AstraZeneca, BMS pull Forxiga in Germany in snit over pricing

Eric Palmer AstraZeneca and Bristol-Myers Squibb look to be feeling good about the future of their diabetes drug Forxiga. The drugmakers have yanked the diabetes treatment from the ...

Court Evades US Concern Over False Claims And Side Effect Reports

esilverman Here is a ruling that is nothing but anticlimactic. After a few months of anticipation, a federal appeals court decided not to rule on an issue raised last summer ...

Idenix fires off a shot in patent battle over Gilead’s sofosbuvir

Damian Garde As Gilead nears a virtually guaranteed FDA approval for the hepatitis C-fighting sofosbuvir, the biotech is facing intellectual property challenges from a bevy of competitors, ...

Catalyst Pharma Fights Greed Charges Over An Orphan Drug

esilverman For the past month, shares in a small developer of novel drugs called Catalyst Pharmaceutical Partners have given up roughly half their value amid an unusual public ...

Israeli Teva workers strike over wage gaps after CEO halts cuts there

Eric Palmer Workers at a Teva Pharmaceutical Industries plant that makes the API for the company's blockbuster Copaxone have walked out, saying they are paid far less than workers ...

US Senator Wants To Probe FDA Over ‘Pay To Play’ Meetings

esilverman A US Senator wants to open an investigation into a behind-the-scenes panel called IMMPACT, which is run privately by a pair of academics, who hold brainstorming ...

CSL Pays $64M To Settle Antitrust Suit Over Plasma Pricing

esilverman After four years of litigation, CSL has agreed to pay $ 64 million to settle antitrust lawsuits in which several hospitals claimed the plasma products supplier ...

Gilead Stopping Idelalisib Study Early Over Positive Risk-Benefit

barbara.lempert Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. ...

Activist investor fumes over Otsuka bid for Astex

Carly Helfand It's a "he said, she said" situation over the true value of Astex Pharmaceuticals. An activist shareholder has thrown up a roadblock for a proposed $ 886 ...

Forget The Apology: Japan To Raid Novartis Offices Over Diovan Scandal

esilverman Japanese authorities plan to raid Novartis offices after a health ministry panel concluded that the drugmaker should be held responsible for using falsified research ...

Takeda Loses Second Actos Trial Over Bladder Cancer Risks

esilverman A Maryland state court jury ordered Takeda Pharmaceuticals to pay $ 1.7 million in damages for failing to properly warn a former US Army translator and his physician ...

UK To Keep Special Cancer Drug Fund As Battle Over NICE Rages

esilverman The pharmaceutical industry has won a victory in the UK, where the government has decided to renew more than $ 300 million in special funding for a controversial ...
Page 3 of 812345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS